PremiumThe Flymanagement to meet with Stephens Nurix Therapeutics price target lowered to $30 from $35 at UBS Hold Rating for Nurix Therapeutics Amid Competitive Challenges and Strategic Uncertainties PremiumRatingsPromising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation Nurix Therapeutics, Inc. Earnings Report: Is it a Beat? Nurix Therapeutics Q1 2025 Financial Highlights PremiumThe FlyNurix Therapeutics announces FDA ODD granted to bexobrutideg Nurix Therapeutics initiated with a Market Perform at Leerink Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status 
